close
Add to watchlist
China Shenghuo Pharmaceutical Holdings Inc (KUN)
China Shenghuo Pharmaceutical Holdings, Inc. and its subsidiaries engage in the research, development, manufacture, and marketing of pharmaceutical, nutritional supplement, and cosmetic products in the People's Republic of China. The company develops products derived from the medicinal herb Panax notoginseng for cardiovascular and cerebrovascular disease, peptic ulcer disease, and health products markets. It offers Xuesaitong soft capsules to treat the symptoms of cardiovascular and cerebrovascular diseases; Qiye ShenÂ’an tablets to relieve headache, insomnia, and palpitation; Banlangen tablets for the treatment of parotitis, pharyngitis, mastitis, and swollen and sore throat due to cold and influenza; Bergenini tablets to relieve cough and phlegm due to bronchial ailments; and Huangtengsu tablets and soft capsules to treat the symptoms of dysentery, enteritis, respiratory tract infections, uncomplicated urethral, surgery infections, and conjunctivitis. The company also provides Danshen tablets to regulate blood circulation and treat the symptoms of blood stasis; Triperygium hypoglaucum Hutch tablets for the treatment of symptoms of rheumatoid arthritis; Tian Xin Soft capsules to reduce blood viscosity and enhance blood circulation; and Radix Polygoni Multiflori capsules to treat effects of weakness of the kidney and liver, fatigue, and dizziness due to blood deficiencies. In addition, its products in Phase II clinical trials include Wei Dingkang soft capsules, Dencichine Hemostat, Levofloxacin Hydrochloride soft capsules, and Brufen soft capsules. Further, the company offers a range of over-the-counter supplements, and vitamin capsules and pills, as well as cosmetic products, including lotions, creams, and other cosmetic items. It sells products under the Lixuwang and Shenhuo brand names through its sales offices, agents, and regional distributors. The company is based in Kunming, the People's Republic of China.
(login to add this stock to your watchlist or favorites)
Key Statistics
| Closing Price | 0.54 |
| Volume | 600 |
| Volume Avg | 9108 |
| 52 Week High | 1.58 |
| 52 Week Low | 0.27 |
| PE | 71.11 |
| PE (group average) | N/A |
| EPS Year | 0.01 |
| EPS change Q/Q | -50% |
| EPS change Q/Q Yr ago | -100% |
| EPS change Q/Q next Q est | -100% |
| EPS change Y/Y | 1000% |
| REV change Q/Q | 0% |
| REV change Q/Q Yr ago | 18.99% |
| EPS next Q est | 0.00 |
| EPS next Y est | 0.00 |
| Divident Annual | 0.00 |
| Dividend Yield | 0% |